These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25487794)

  • 21. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.
    Livermore DM; Mushtaq S; Doumith M; Jamrozy D; Nichols WW; Woodford N
    J Antimicrob Chemother; 2018 Dec; 73(12):3336-3345. PubMed ID: 30247546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
    Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.
    Kazmierczak KM; Biedenbach DJ; Hackel M; Rabine S; de Jonge BL; Bouchillon SK; Sahm DF; Bradford PA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4490-500. PubMed ID: 27161636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
    Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG; Bradford PA; Yates K; Newell P
    J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.
    Lahiri SD; Alm RA
    Antimicrob Agents Chemother; 2016 May; 60(5):3183-6. PubMed ID: 26926646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
    Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Stone GG; Newell P; Bradford PA
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
    Winkler ML; Papp-Wallace KM; Bonomo RA
    J Antimicrob Chemother; 2015 Aug; 70(8):2279-86. PubMed ID: 25957381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
    Keepers TR; Gomez M; Celeri C; Nichols WW; Krause KM
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5297-305. PubMed ID: 24957838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.
    Hackel M; Kazmierczak KM; Hoban DJ; Biedenbach DJ; Bouchillon SK; de Jonge BL; Stone GG
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4677-83. PubMed ID: 27216054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.
    Nichols WW; Stone GG; Newell P; Broadhurst H; Wardman A; MacPherson M; Yates K; Riccobene T; Critchley IA; Das S
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30061279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012-2016.
    Ramalheira E; Stone GG
    J Glob Antimicrob Resist; 2019 Dec; 19():106-115. PubMed ID: 31295583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.
    Lahiri SD; Walkup GK; Whiteaker JD; Palmer T; McCormack K; Tanudra MA; Nash TJ; Thresher J; Johnstone MR; Hajec L; Livchak S; McLaughlin RE; Alm RA
    J Antimicrob Chemother; 2015; 70(6):1650-8. PubMed ID: 25645206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).
    de Jonge BL; Karlowsky JA; Kazmierczak KM; Biedenbach DJ; Sahm DF; Nichols WW
    Antimicrob Agents Chemother; 2016 May; 60(5):3163-9. PubMed ID: 26926648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.
    Coleman K; Levasseur P; Girard AM; Borgonovi M; Miossec C; Merdjan H; Drusano G; Shlaes D; Nichols WW
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3366-72. PubMed ID: 24687507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.